Pharma News, 2019

A Mayo Clinic-led study involving 488 cardiac patients whose cases were followed for up to 12 years finds that microvascular endothelial dysfunction, a common early sign of cardiovascular disease, is ...

Doctors may some day be able to reverse the damage that years of heavy drinking does to the liver, a new study suggests.

Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.

Gilead has announced a new strategic collaboration with Glympse, in order to explore the use of biomarker technology in nonalcoholic steatohepatitis (NASH) clinical development.

MorphoSys, Novartis and Galapagos have announced the premature end of the clinical development program of MOR106 in atopic dermatitis, citing “low probability to meet main goal of study.

AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europ...

An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evalu...

(Reuters) - Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer’s disease therapy Namenda, the drugmaker said, in a resolution...

Working with model mice, post-mortem human brains, and people with schizophrenia, researchers at the RIKEN Center for Brain Science in Japan have discovered that a subtype of schizophrenia is related ...

Australian researchers have found little evidence that medicinal cannabis can relieve mental illnesses such as anxiety, depression and psychosis.

AVROBIO, Inc.

DUBLIN, Oct.